2. Search Result
Search Result
Results for "

α-Synuclein aggregation inhibitor

" in MedChemExpress (MCE) Product Catalog:

58

Inhibitors & Agonists

2

Fluorescent Dyes

9

Peptides

12

Natural
Products

4

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-114118
    Semaglutide
    Maximum Cited Publications
    35 Publications Verification

    		 GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide
  • HY-101855
    Emrusolmin

    Anle138b

    		 Amyloid-β Neurological Disease
    Emrusolmin (Anle138b), an oligomeric aggregation inhibitor, blocks the formation of pathological aggregates of prion protein (PrPSc) and of α-synuclein (α-syn). Emrusolmin strongly inhibits oligomer accumulation, neuronal degeneration, and disease progression in vivo. Emrusolmin has low toxicity and an excellent oral bioavailability and blood-brain-barrier penetration. Emrusolmin blocks Aβ channels and rescues disease phenotypes in a mouse model for amyloid pathology .
    Emrusolmin
  • HY-D0914
    Fast Green FCF

    FD&C Green No. 3; Food green 3; C.I. 42053

    		 Environmental Pollutants α-synuclein Neurological Disease
    Fast Green FCF is a sea green triarylmethane food dye, with absorption maximum ranging from 622 to 626 nm. Fast Green FCF inhibits α-synuclein aggregation, as well as Aβ and P2X4 receptor, and TLR4/Myd88/NF-κB. Fast Green FCF is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function .
    Fast Green FCF
  • HY-114118B
    Semaglutide acetate
    Maximum Cited Publications
    35 Publications Verification

    		 GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide acetate
  • HY-114118A
    Semaglutide TFA
    Maximum Cited Publications
    35 Publications Verification

    		 GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide TFA
  • HY-114118CP
    Semaglutide (crude)

    		GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide (crude) is the crude form of Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances Autophagy, inhibits oxidative stress and Apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide (crude)
  • HY-160116
    α-Synuclein aggregate binder 1

    		Radionuclide-Drug Conjugates (RDCs) Fluorescent Dye α-synuclein Neurological Disease
    α-Synuclein aggregate binder 1 (Compound C05-05) is a specific binder for α-synuclein aggregates and can inhibit α-synuclein aggregation. α-Synuclein aggregate binder 1 can be used as a fluorescent probe (excitation wavelength 900 nm, detection wavelength 500-550 nm) for optical imaging, and can also inhibit α-synuclein fibril formation by blocking the aggregation process. α-Synuclein aggregate binder 1 can be used for positron emission tomography (PET) imaging after being labeled with 18F. α-Synuclein aggregate binder 1 can be used for visual diagnosis of brain lesions and mechanism research of neurodegenerative diseases such as Parkinson's disease and Lewy body dementia .
    α-Synuclein aggregate binder 1
  • HY-114118S3
    Semaglutide-13C6,15N TFA

    		Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Metabolic Disease
    Semaglutide- 13C6, 15N TFA is the 13C- and 15N-labeled Semaglutide TFA (HY-114118A). Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide-13C6,15N TFA
  • HY-B0512
    Sulfamerazine
    4 Publications Verification

    RP2632

    		 Antibiotic Bacterial α-synuclein Infection Neurological Disease
    Sulfamerazine (RP2632) is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine can be used for the research of Parkinson’s disease and bacterial infection .
    Sulfamerazine
  • HY-120475
    PBT434
    2 Publications Verification

    ATH434

    		 α-synuclein Neurological Disease
    PBT434 is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 has the potential for the research of Parkinson’s disease (PD) .
    PBT434
  • HY-W010041
    Scyllo-Inositol

    		α-synuclein Amyloid-β Neurological Disease
    Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .
    Scyllo-Inositol
  • HY-Y0790
    Cuminaldehyde
    1 Publications Verification

    p-Isopropylbenzaldehyde

    		 Environmental Pollutants α-synuclein Infection Neurological Disease Inflammation/Immunology Cancer
    Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC50= 0.00085 mg/mL), α-glucosidase (IC50=0.5 mg/mL) and lipoxygenase (IC50=1370 μM). Cuminaldehyde also inhibits the fibrillation of α-synuclein and prevents its aggregation. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .
    Cuminaldehyde
  • HY-N0698
    Crocin II

    		Endogenous Metabolite α-synuclein Neurological Disease Cancer
    Crocin II is an inhibitor targeting α-synuclein aggregation, with a IC50 of 0.541 μM and a EC50 of 3.63 μM. Crocin II inhibits α-synuclein aggregation and dissociates pre-formed α-synuclein fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers .
    Crocin II
  • HY-124876
    SynuClean-D
    1 Publications Verification

    SC-D

    		 α-synuclein Neurological Disease
    SynuClean-D (SC-D) is an inhibitor of α-synuclein aggregation, disrupts mature amyloid fibrils, prevents fibril propagation, and abolishes the degeneration of dopaminergic neurons in an animal model of Parkinson’s disease .
    SynuClean-D
  • HY-145580
    Minzasolmin

    UCB0599; (R)-NPT200-11

    		 α-synuclein Neurological Disease
    Minzasolmin (UCB0599; (R)-NPT200-11) is an orally active, blood-brain-permeable α-synuclein (α-Syn) inhibitor that selectively binds to α-Syn misfolded intermediates (such as oligomers) and inhibits aggregation and fibril formation by regulating their conformational stability. Minzasolmin can reduce the generation of pathological oligomers and block neurotoxic signaling, thereby reducing the abnormal accumulation of α-Syn in the brain. Minzasolmin significantly improved motor deficits, reduced neuroinflammatory markers, and α-Syn-related pathological deposition in transgenic mouse models .
    Minzasolmin
  • HY-114118S
    Semaglutide-d8

    		Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide-d8
  • HY-114118S1
    Semaglutide-d8 tetraTFA

    		Isotope-Labeled Compounds GLP Receptor Insulin Receptor α-synuclein Apoptosis p38 MAPK Autophagy Bcl-2 Family Neurological Disease Metabolic Disease Cancer
    Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
    Semaglutide-d8 tetraTFA
  • HY-N0901A
    Corynoxine B
    5 Publications Verification

    		 α-synuclein Neurological Disease Cancer
    Corynoxine B is an alkaloid-based autophagy inducer and α-synuclein aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances α-synuclein (α-syn) clearance in Parkinson's disease mice .
    Corynoxine B
  • HY-156586
    Egalognastat

    ASN90

    		 OGA Tau Protein Neurological Disease
    Egalognastat (ASN90) is a selective, brain-penetrant and orally active O-GlcNAcase (OGA) enzyme inhibitor with an IC50 value of 10.2 nM. Egalognastat increases O-GlcNAcylation of intracellular proteins like tau and α-synuclein, preventing their aggregation and toxicity. Egalognastat does not inhibit hexosaminidase (Hex). Egalognastat can be used for the research of neurodegenerative diseases, such as tauopathies and α-synucleinopathies (e.g., Alzheimer’s disease and Parkinson’s disease) .
    Egalognastat
  • HY-171705
    KMS99220

    		Keap1-Nrf2 AMPK JNK IKK p38 MAPK NO Synthase α-synuclein Interleukin Related Neurological Disease
    KMS99220 is an orally active, blood-brain barrier-permeable activator of the Nrf2 inhibitory protein Keap-1. KMS99220 enhances the activity of AMPK, activates the Nrf2 signaling pathway, and reduces the phosphorylation of IκB, nuclear translocation of NFκB, as well as the phosphorylation levels of JNK, IKK and p38 MAPK via HO-1. KMS99220 binds to Keap1 to trigger the nuclear translocation of Nrf2, induces the expression of HO-1, NQO1, GCLC, GCLM and proteasome subunits; enhances proteasomal enzymatic activity; inhibits iNOS expression, nitric oxide production and IL-1β generation; attenuates microglial activation; reduces α-synuclein aggregation; and prevents dopaminergic neuron degeneration and motor dysfunction. KMS99220 prevents the degeneration of dopaminergic neurons in the substantia nigra, induces the expression of Nrf2 downstream target genes, and effectively ameliorates associated motor dysfunction in a mouse model of Parkinson's disease. KMS99220 is applicable to research related to Parkinson's disease .
    KMS99220
  • HY-120475A
    PBT434 mesylate
    2 Publications Verification

    ATH434 mesylate

    		 α-synuclein Neurological Disease
    PBT434 methanesulfonate is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 methanesulfonate can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 methanesulfonate inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 methanesulfonate prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 methanesulfonate has the potential for the research of Parkinson’s disease (PD) .
    PBT434 mesylate
  • HY-125287
    (Rac)-Minzasolmin

    (Rac)-UCB0599; NPT200-11

    		 α-synuclein Neurological Disease
    (Rac)-Minzasolmin ((Rac)-UCB0599; NPT200-11) is a blood-brain barrier penetrated alpha-synuclein (ASYN) misfolding inhibitor. (Rac)-Minzasolmin acts on the early stage of ASYN aggregation process, by replacing the membrane-bound oligomers ASYN, allowing them to revert to the monomeric form, while preventing pathological aggregation. (Rac)-Minzasolmin effectively improves the ASYN deposition in the retina and the neuro-pathological indicators in two α-synuclein transgenic mouse models. (Rac)-Minzasolmin can be used for the studies of Parkinson's disease (PD) and dementia with Lewy bodies (DLB) .
    (Rac)-Minzasolmin
  • HY-P5082
    α-Synuclein 4554W

    		α-synuclein Neurological Disease
    α-Synuclein 4554W is an inhibitor of α-Synuclein (aSyn) aggregation with associated toxicity. α-Synuclein 4554W consists of GIVNGVKA sequences, previously identified through intracellular library screening. α-Synuclein 4554W reduces fibril formation of aSyn mutants assocaited with Parkinson’s disease .
    α-Synuclein 4554W
  • HY-157308
    α-Synuclein inhibitor 10

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 10 (compound a8) inhibits the activity of α-Syn aggregation with low IC50 value (1.08 μM). α-Synuclein inhibitor 10 exhibits good binding affinity to α-Syn residues. α-Synuclein inhibitor 10 can be used in the research of Parkinson's disease (PD) .
    α-Synuclein inhibitor 10
  • HY-B0512A
    Sulfamerazine sodium

    RP2632 sodium

    		 Antibiotic Bacterial α-synuclein Infection Neurological Disease
    Sulfamerazine (RP2632) sodium is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine sodium inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine sodium inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine sodium can be used for the research of Parkinson’s disease and bacterial infection .
    Sulfamerazine sodium
  • HY-153416
    QR-0217

    		Amyloid-β Neurological Disease
    QR-0217 is a potent Aβ1-40 aggregation inhibitor with an IC50 value of 7.5 µM. QR-0217 inhibits α-synuclein aggregation. QR-0217 reduces memory impairments caused by Aβ neurotoxicity .
    QR-0217
  • HY-N10306
    Sycosterol A

    		α-synuclein Neurological Disease
    Sycosterol A is a sterol-based α-synuclein (α-syn) inhibitor that targets α-synuclein aggregates and inhibits α-synuclein aggregation. Sycosterol A can be used in the study of anti-neurodegenerative diseases .
    Sycosterol A
  • HY-N15613
    α-Synuclein inhibitor 14

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 14 (Compound 3) is a diarylheptanoid that can be isolated from Alpinia officinarum. α-Synuclein inhibitor 14 can inhibit the aggregation of α-synuclein, with an inhibition rate of 72.4% at a concentration of 10 μM. α-Synuclein inhibitor 14 can be used in the research of neurodegenerative diseases such as Parkinson's disease .
    α-Synuclein inhibitor 14
  • HY-175737
    α-synuclein-IN-16

    		α-synuclein Neurological Disease
    α-synuclein-IN-16 (Compound H1) is a α-synuclein inhibitor. α-synuclein-IN-16 significantly inhibits the secondary nucleation in α-synuclein aggregation. α-synuclein-IN-16 can be used for Parkinson’s disease research .
    α-synuclein-IN-16
  • HY-163519
    α-Synuclein inhibitor 13

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 13 is an inhibitor of α-synuclein (α-Syn). α-Synuclein inhibitor 13 inhibits the aggregation of α-Syn proteins and is able to break down formed fibers. It is mainly used in Parkinson's disease research .
    α-Synuclein inhibitor 13
  • HY-120475B
    PBT434 free base

    ATH434 free base

    		 α-synuclein Neurological Disease
    PBT434 (ATH434) free base is a potent, orally active and cross the blood-brain barrier α-synuclein aggregation inhibitor. PBT434 free base can be used as a iron chelator and modulates transcellular iron trafficking. PBT434 free base inhibits iron-mediated redox activity and iron-mediated aggregation of α-synuclein. PBT434 free base prevents the loss of substantia nigra pars compacta neurons (SNpc). PBT434 free base has the potential for the research of Parkinson’s disease (PD) .
    PBT434 free base
  • HY-N16524
    Alpinin A

    		α-synuclein Neurological Disease
    Alpinin A is a diarylheptanoid found in the rhizomes of Alpinia officinarum. Alpinin A can strongly inhibit the aggregation of α-synuclein with inhibition rate of 66% at 10 μM. Alpinin A can be used for the research of neurological disease, such as Parkinson’s disease .
    Alpinin A
  • HY-170553
    ZPD-2

    		α-synuclein Neurological Disease
    ZPD-2 inhibits the aggregation of C-terminally truncated and full-length α-synuclein. ZPD-2 inhibits the formation and fibrillation of α-Syn, thereby preventing its propagation. ZPD-2 can be used in research of Parkinson's disease .
    ZPD-2
  • HY-147644
    α-Synuclein inhibitor 3

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 3 (Compound 7g) is a α-synuclein (α -Syn) aggregation inhibitor. α-Synuclein inhibitor 3 can be used for Parkinson’s disease research .
    α-Synuclein inhibitor 3
  • HY-152552
    α-Synuclein inhibitor 8

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 8 is an active inhibitor of α-Synuclein with an IC50 value of 2.5 µM. α-Synuclein inhibitor 8 has highly inhibition on the aggregation and disaggregation of α-Synuclein fibers. α-Synuclein inhibitor 8 reduces the formation of inclusions in neurons that can repairs damage neurons and improves Parkinson’s disease (PD)-like symptoms. α-Synuclein inhibitor 8 has high antioxidant activity and low cytotoxicity .
    α-Synuclein inhibitor 8
  • HY-149509
    α-Synuclein inhibitor 9

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 9 (Compound 20C) is an α-Synuclein inhibitor. α-Synuclein inhibitor 9 binds to cavities in mature α-synuclein fibrils and reduces the β-sheet structure. α-Synuclein inhibitor 9 inhibits A53T α-Syn aggregation. α-Synuclein inhibitor 9 has neuroprotective effect, improves brain functional connection and relieves motor dysfunction.α-Synuclein inhibitor 9 can be used for Parkinson’s disease (PD) research. .
    α-Synuclein inhibitor 9
  • HY-157806
    α-Synuclein inhibitor 12

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 12 (compound 4ce) is an inhibitor of α-Syn (α-synuclein) aggregation and can be used in the study of neurological diseases .
    α-Synuclein inhibitor 12
  • HY-Y0790R
    Cuminaldehyde (Standard)

    p-Isopropylbenzaldehyde (Standard)

    		 α-synuclein Reference Standards Infection Neurological Disease Inflammation/Immunology Cancer
    Cuminaldehyde Standard is the analytical standard of Cuminaldehyde. This product is intended for research and analytical applications. Cuminaldehyde is the main component of Cuminum cyminum and has multiple biological activities, including anti-inflammatory, anti-cancer, anti-diabetic, anti-injury, anti-neuropathy and antibacterial effects. Cuminaldehyde is an inhibitor of aldose reductase (IC50= 0.00085 mg/mL) and α-glucosidase (IC50=0.5 mg/mL). Cuminaldehyde also inhibits the fibrillation of α-synuclein and prevents its aggregation Cuminaldehyde can induce apoptosis in colon adenocarcinoma cells by targeting topoisomerase I and II. In addition, Cuminaldehyde also exerts anti-inflammatory activity by inhibiting lipoxygenase. Cuminaldehyde has a strong inhibitory effect on the growth of Aspergillus flavus and the biosynthesis of aflatoxin B1 (AFB1). Cuminaldehyde can exert anti-injury and anti-neuropathy effects by participating in opioid receptors, L-arginine/NO/cGMP pathways and anti-inflammatory effects. Cuminaldehyde has potential application value in the research of neurodegenerative diseases, cancer, diabetes and neuropathic pain diseases .
    Cuminaldehyde (Standard)
  • HY-147666
    α-Synuclein inhibitor 4

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 4 (compound 3gh) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 0.98 μM and inhibition ratio at 30 μM of 91.2% .
    α-Synuclein inhibitor 4
  • HY-147667
    α-Synuclein inhibitor 5

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 5 (compound 4aa) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 1.22 μM and inhibition ratio at 30 μM of 94.3% .
    α-Synuclein inhibitor 5
  • HY-147669
    α-Synuclein inhibitor 7

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 7 (compound 3gf) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 1.95 μM and inhibition ratio at 30 μM of 85.8% .
    α-Synuclein inhibitor 7
  • HY-147668
    α-Synuclein inhibitor 6

    		α-synuclein Neurological Disease
    α-Synuclein inhibitor 6 (compound 3ge) is a potent and BBB-penetrated inhibitor of α-Synuclein (α-Syn) aggregation, with an IC50 of 1.70 μM and inhibition ratio at 30 μM of 94.4% .
    α-Synuclein inhibitor 6
  • HY-144696
    Dyrk1A/α-synuclein-IN-2

    		DYRK Neurological Disease
    Dyrk1A/α-synuclein-IN-2 (Compound b20) is a dual Dyrk1A and α-synuclein aggregation inhibitor with an IC50 of 7.8 µM for α-synuclein. Dyrk1A/α-synuclein-IN-2 has high predictive CNS penetration and neuroprotective effect .
    Dyrk1A/α-synuclein-IN-2
  • HY-130398
    Aerophobin-2

    		α-synuclein Neurological Disease
    Aerophobin-2 is a bromine compound, which can be isolated from sponge Verongia aerophoba. Aerophobin-2 inhibits aggregation of α-synuclein (α-syn) and phosphorylated α-synuclein (pSyn), exhibits neuroprotective efficacy .
    Aerophobin-2
  • HY-N0698R
    Crocin II (Standard)

    		Reference Standards Endogenous Metabolite α-synuclein Neurological Disease Cancer
    Crocin II (Standard) is the analytical standard of Crocin II. This product is intended for research and analytical applications. Crocin II is an inhibitor targeting α-synuclein aggregation, with a IC50 of 0.541 μM and a EC50 of 3.63 μM. Crocin II inhibits α-synuclein aggregation and dissociates pre-formed α-synuclein fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers.
    Crocin II (Standard)
  • HY-N0901AR
    Corynoxine B (Standard)

    		α-synuclein Reference Standards Neurological Disease Cancer
    Corynoxine B Standard is an analytical standard for Corynoxine B. This product is intended for research and analytical applications. Corynoxine B is an alkaloid-type autophagy inducer and α-synuclein aggregation inhibitor that ameliorates Mn-induced dysregulation of autophagy and enhances the clearance of α-synuclein (α-syn) in Parkinson's disease mice .
    Corynoxine B (Standard)
  • HY-144695
    Dyrk1A/α-synuclein-IN-1

    		DYRK Neurological Disease
    Dyrk1A/α-synuclein-IN-1 (Compound b1) is a dual Dyrk1A and α-synuclein aggregation inhibitor with IC50 values of 177 nM and 10.5 µM, respectively. Dyrk1A/α-synuclein-IN-1 has high predictive CNS penetration and neuroprotective effect .
    Dyrk1A/α-synuclein-IN-1
  • HY-163739
    LETC

    		α-synuclein Neurological Disease
    LETC is an orally active α-synuclein (α-Syn) aggregation inhibitor with an EC50 of 66 nM in transfected DH60.21 neuroblastoma cells. LETC can cross the blood-brain barrier. LETC can be used for the study of synucleinopathies .
    LETC
  • HY-P10404
    PDpep1.3

    		α-synuclein Others Neurological Disease
    PDpep1.3 is a peptide inhibitor of α-synuclein that disrupts the direct interaction between α-synuclein and CHarged Multivesicular body Protein 2B (CHMP2B). As a result, PDpep1.3 restores the degradation function of endosomes and lysosomes, reduces the protein level and aggregation of α-synuclei, and protects dopaminergic neurons from α-synuclei-mediated degeneration. PDpep1.3 can be used to study neurodegenerative diseases and protein-protein interactions .
    PDpep1.3
  • HY-W010041R
    Scyllo-Inositol (Standard)

    		Reference Standards α-synuclein Amyloid-β Neurological Disease
    Scyllo-Inositol is an inhibitor that targets the aggregation of misfolded proteins (such as α-synuclein and Amyloid-β), is orally effective, and can cross the blood-brain barrier. Scyllo-Inositol can selectively bind to and stabilize non-toxic oligomers, preventing them from converting into toxic fibers, exerting protein homeostasis regulation and neuroprotective activity. Scyllo-Inositol binds to the hydrophobic region of pathogenic proteins, inhibits protein aggregation, and promotes lysosome- and proteasome-mediated degradation pathways, thereby reducing neurotoxicity. Scyllo-Inositol can be used in the study of neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, and Huntington's disease .
    Scyllo-Inositol (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: